Aptol Pharma ApS: Financial statements 2018
CVR: 39308967
Source: annual report 2018, Danish Business Authority
05/02/2018 – 31/12/2018
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 89,482 and a net result of DKK 128,964. Equity in the 2018 report amounted to DKK 50,000. The solvency ratio was 66.3%.
- Revenue
- DKK 0
- Gross Profit
- DKK 89,482
- Profit/Loss
- DKK 128,964
- Equity
- DKK 50,000
- Total Assets
- DKK 75,402
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of February 5, 2018, Kira Gerber Petersen has joined the board of directors of Aptol Pharma ApS.
As of February 5, 2018, Kira Gerber Petersen is registered as director of Aptol Pharma ApS.
Aptol Pharma ApS was founded on February 5, 2018.
About Aptol Pharma ApS
Aptol Pharma ApS was a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include ADT HOLDING ApS, Tue Wenzel Kragstrup and Peter Andreas Nicolai Reumert Wagtmann. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity in the 2024 report amounted to DKK -140,336.